UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy TPF Induction chemotherapy TPF 3 Cycles3 Cycles
Docetaxel 75mg/mDocetaxel 75mg/m22 d1 d1
Cisplatin 100mg/mCisplatin 100mg/m2 2 d1d1
5-FU 1000mg/m5-FU 1000mg/m2 2 d1-4d1-4
Induction chemotherapy TPF Induction chemotherapy TPF 3 Cycles3 Cycles
Docetaxel 75mg/mDocetaxel 75mg/m22 d1 d1
Cisplatin 100mg/mCisplatin 100mg/m2 2 d1d1
5-FU 1000mg/m5-FU 1000mg/m2 2 d1-4d1-4
RadiochemotherapyRadiochemotherapy 70 Gy + Cisplatin 100 mg /m70 Gy + Cisplatin 100 mg /m22 d1, 22, 43 d1, 22, 43
RadiochemotherapyRadiochemotherapy 70 Gy + Cisplatin 100 mg /m70 Gy + Cisplatin 100 mg /m22 d1, 22, 43 d1, 22, 43
Laryngoprotect-StudyLaryngoprotect-StudyR. Knecht et al.R. Knecht et al.
Laryngoprotect-StudyLaryngoprotect-StudyR. Knecht et al.R. Knecht et al.
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Regions and stages in %Regions and stages in %Regions and stages in %Regions and stages in %
55%55%
24%24%
21%21%
T/NT/N
4
4
13
21
2
3
3
8
NN11 NN22 NN33
2525
3434
2525
3434
2
3
-
5
TT22
TT33
TT44
15
35
50
100
NN00
Stage IIStage II Stage IIIStage III Stage IVStage IV
7
66
n=103n=103
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Toxicity Toxicity (WHO Grad III / IV)(WHO Grad III / IV)Toxicity Toxicity (WHO Grad III / IV)(WHO Grad III / IV)
RenalRenal 25%25%
Afebrile Neutropenia Afebrile Neutropenia 95%95%
Nausea/VomitingNausea/Vomiting 25%25%
Mucositis Mucositis 10%10%
Sensory NeuropathySensory Neuropathy 10%10%
4%4%
47%47%
20%20%
43%43%
5%5%
InductionInductionchemotherapychemotherapy
Radio-Radio-chemotherapychemotherapy
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
SupraglottisSupraglottis
GlottisGlottis
Hypopharynx Hypopharynx
SupraglottisSupraglottis
GlottisGlottis
Hypopharynx Hypopharynx
RRRRRRRR
76%76%
73%73%
92%92%
79%79%
76%76%
73%73%
92%92%
79%79%
41%41%
53%53%
54%54%
47%47%
41%41%
53%53%
54%54%
47%47%
CRCRCRCR
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpost
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
prae
S. A., T3N3M0
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postprae
B. W., T2N1M0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
prae
B. W., T2N1M0post
ResultsResultsafter TPF - Polychemotherapy(3 Cycles)after TPF - Polychemotherapy(3 Cycles)
ResultsResultsafter TPF - Polychemotherapy(3 Cycles)after TPF - Polychemotherapy(3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpostpraeprae
M. B., T2N1M0M. B., T2N1M0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
postpostprae prae
B. H., T2N2bM0B. H., T2N2bM0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpost
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
prae prae
G. H., T2N2bM0G. H., T2N2bM0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpost
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
prae prae
J. H., T2N2bM0J. H., T2N2bM0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Laryngoprotect n = 103
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
74% 74% 75%75%
2% 2% 93%93%
74% 74% 75%75%
2% 2% 93%93%
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
2 years
ResultsResultsHypopharynxHypopharynxResultsResultsHypopharynxHypopharynx
Knecht R . et al. Knecht R . et al. (2004)(2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induktion chemotherapy Induktion chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induktion chemotherapy Induktion chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
2 years
Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103
91% 91% 85%85%
0% 0% 94%94%
91% 91% 85%85%
0% 0% 94%94%
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
ResultsResultsLarynxLarynx
ResultsResultsLarynxLarynx
Knecht R . et al. Knecht R . et al. (2004)(2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
2 years
Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103
91% 91% 85%85%
0% 0% 94%94%
91% 91% 85%85%
0% 0% 94%94%
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
ResultsResultsLarynxLarynx
ResultsResultsLarynxLarynx
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RTOG 91-11 n = 172
88% 88% 61%61%
8% 8% 74%74%
88% 88% 61%61%
8% 8% 74%74%
Knecht R . et al. Knecht R . et al. (2004)(2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Laryngoprotect 2Laryngoprotect 2Laryngoprotect 2Laryngoprotect 2
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
22
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Radiochemotherapy Radiochemotherapy 70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m2 2 total)total)
Radiochemotherapy Radiochemotherapy 70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m2 2 total)total)
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Cetuximab (400 mg d1; 250mg ab d8 wöchtl)(400 mg d1; 250mg ab d8 wöchtl)
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Cetuximab (400 mg d1; 250mg ab d8 wöchtl)(400 mg d1; 250mg ab d8 wöchtl)
International principal investigator: R. KnechtInternational principal investigator: R. KnechtInternational principal investigator: R. KnechtInternational principal investigator: R. Knecht
Stage III/IVStage III/IVStage III/IVStage III/IV
EGFR-Antibody EGFR-Antibody Neoadjuvant Primary TherapyNeoadjuvant Primary Therapy EGFR-Antibody EGFR-Antibody
Neoadjuvant Primary TherapyNeoadjuvant Primary Therapy
Top Related